Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors
NCT06157892 · View on ClinicalTrials.gov ↗
Study Summary
This clinical trial is studying solid tumor cancers. A solid tumor is one that starts in part of your body like your lungs or liver instead of your blood. Once they've grown bigger in one spot or spread to other parts of the body, they're harder to treat. This is called advanced or metastatic cancer. Participants in this study must have breast cancer or gastric cancer. Participants must have tumors that have HER2 on them. This allows the cancer to grow more quickly or spread faster. There are few treatment options for patients with advanced or metastatic solid tumors that express HER2. This clinical trial uses an experimental drug called disitamab vedotin (DV). Disitamab vedotin is a type of antibody drug conjugate or ADC. ADCs are designed to stick to cancer cells and kill them. This clinical trial uses a drug called tucatinib, which has been approved to treat cancer in the United States and some other countries. This drug is sold under the brand name TUKYSA®. This study will test how safe and how well DV with tucatinib works for participants with solid tumors. This study will also test what side effects happen when participants take these drugs. A side effect is anything a drug does to the body besides treating the disease.
Conditions Studied
Interventions
- DRUG disitamab vedotin
- DRUG tucatinib
Study Locations (20)
Arizona
- Banner-University Medical Center Tucson Campus — Tucson
- Banner-University Medical Center Tucson Campus — Tucson
- The University of Arizona Cancer Center-North Campus Pharmacy, Attn: Kelly Myrdal — Tucson
- University of Arizona Cancer Center - North Campus — Tucson
- The University of Arizona Cancer Center-Main — Tucson
California
- UC Irvine Health - Chao Family Comprehensive Cancer Center — Orange
- UC Irvine Medical Center — Orange
- University of California, San Francisco | HDFCCC - Hematopoietic Malignancies — San Francisco
- UCLA Department of Medicine - Hematology & Oncology — Santa Monica
- UCLA Hematology/Oncology - Parkside — Santa Monica
Florida
- Moffitt Cancer Center - International Plaza — Tampa
- H. Lee Moffitt Cancer Center and Research Institute — Tampa
- Moffitt Cancer Center - McKinley Campus — Tampa
- Moffitt McKinley Hospital — Tampa
Colorado
- Colorado West Healthcare System, dba Community Hospital — Grand Junction
- Colorado West Healthcare, dba Grand Valley Oncology — Grand Junction
Connecticut
- Danbury Hospital — Danbury
- The Whittingham Cancer Center / Norwalk Hospital — Norwalk
District of Columbia
- Georgetown University Medical Center — Washington D.C.
- MedStar Georgetown University Hospital — Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 172 participants |
| Start Date | 2024-05-20 |
| Est. Completion | 2029-07-28 |
| Phase | Phase 2 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06157892
The ClinicalTrials.gov registry entry for NCT06157892 describes a study currently listed as recruiting. It is categorized as Phase 2, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 172 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Seagen, a wholly owned subsidiary of Pfizer, which has 51 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 10 conditions, with Metastatic Breast Cancer appearing as the primary indexed condition, and to 2 interventions — of which disitamab vedotin is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT06157892 reports 20 study locations spanning 6 distinct geographic areas — top geographies include Arizona, California, Florida. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT06157892 about?
NCT06157892 is a clinical study titled "A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors". This clinical trial is studying solid tumor cancers. A solid tumor is one that starts in part of your body like your lungs or liver instead of your blood. Once they've grown bigger in one spot or spread to other parts of the body, they're harder to treat. This is called advanced or metastatic cancer...
What is the current status of trial NCT06157892?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 172 participants. The study started on 2024-05-20. Estimated completion is 2029-07-28.
What conditions does trial NCT06157892 study?
This clinical trial studies the following conditions: Metastatic Breast Cancer, Breast Neoplasms, Gastroesophageal Junction Adenocarcinoma, Advanced Breast Cancer, Triple Negative Breast Neoplasms. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT06157892?
The interventions under investigation include: disitamab vedotin (DRUG), tucatinib (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT06157892?
This trial is sponsored by Seagen, a wholly owned subsidiary of Pfizer, which has 51 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT06157892 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Connecticut, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.